An investigation for investors in Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) shares over potential securities laws violations by Adamas Pharmaceuticals, Inc. was announced.
San Diego, CA -- (SBWIRE) -- 06/05/2019 -- An investigation on behalf of investors of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) shares over potential securities laws violations by Adamas Pharmaceuticals, Inc. was announced.
Investors who purchased shares of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Adamas Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Emeryville, CA based Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. Adamas Pharmaceuticals, Inc completed its Second Public Offering in January 2018 ("SPO"), offering shares at $41.50 per share.
According to the investigation prior to the launch of Adamas Pharmaceuticals' drug Gocovri, a medicine used to treat dyskinesia in Parkinson's disease patients treated with levodopa therapy, Adamas Pharmaceuticals, Inc knew it had substantial roadblocks that would dramatically reduce Adamas' ability to sell Gocovri. According to the investigation Adamas Pharmaceuticals, Inc failed to disclosed these problems in its SPO and thus, misled the market.
In October 2018, Merrill Lynch released a study which casted serious doubt on Gocovri's ability to achieve a sizeable market share and emphasized that According to the investigation failed to include critical information. In March 2019, Adamas Pharmaceuticals, Inc backtracked on prior issued growth estimates and no longer made predictions regarding Gocovri's ability to achieve a sizeable market share.
Shares of Adamas Pharmaceuticals, Inc (NASDAQ: ADMS) declined from $43.61 per share on January 2018 to as low as $4.56 per share on May 30, 2019.
Those who purchased shares of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in conftact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels